VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD, DME and RVO
Visara, a NovaBridge Majority-Owned Subsidiary, Holds Global Rights to VIS-101 Outside of Greater China and Certain Asian Territories
ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) — NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that it will host a virtual business update call on Monday, March 9, 2026, at 9:00 AM ET to review Phase 2a clinical data for VIS-101 in patients with wet age-related macular degeneration (wet AMD).
VIS-101 is a purpose-designed, bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor, designed to provide more potent and durable treatment benefits for patients with wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). VIS-101 is currently completing a randomized, dose-ranging Phase 2a study for wet AMD.
NovaBridge is the majority shareholder of Visara, Inc. (“Visara”). Visara holds global development and commercialization rights to VIS-101 outside of Greater China and certain other Asian territories, which are licensed to Everest Medicines.
Click here to register for the virtual webcast, which will begin at 9:00 AM ET.
Call Participants:
-
Sean Fu, PhD, Chief Executive Officer of NovaBridge
-
Emmett T. Cunningham, Jr., MD, PhD, MPH, Co-founder and Executive Chairman of Visara and Vice Chairman of the NovaBridge Board of Directors
-
Cadmus Rich, MD, MBA, Chief Medical Officer of Visara
-
Carlos Quezada-Ruiz, MD, FASRS, Chair of the Scientific Advisory Board of Visara
-
Nikolas JS London, MD, FACS, Managing Partner, President and Director of Research, Retina Consultants San Diego
The live and archived webcast can also be accessed by visiting the News & Events page of the NovaBridge website. A replay of the webcast will be archived for at least 90 days.
About Visara
Visara is a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics. The Company is led by Co-Founder and Executive Chairman Emmett T. Cunningham, Jr., MD, PhD, MPH, a physician, innovator, entrepreneur, and investor and internationally recognized specialist in infectious and inflammatory eye disease. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
